An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

ATR-CHEK1 signalling is critical for genomic stability. ATR-CHEK1 signalling may be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. We investigated ATR, CHEK1 and phosphorylated CHEK1 (Ser345) protein (pCHEK1) levels in 1712 breast cancers. ATR and CHEK1 mRNA expression was evaluated in 1950 breast cancers. Pre-clinically, biological consequences of AT...

Tree-based model for breast cancer prognostication.

PURPOSE To define prognostic groups for recurrence-free survival in breast cancer, assess relative effects of prognostic factors, and examine the influence of treatment variations on recurrence-free survival in patients with similar prognostic-factor profiles. PATIENTS AND METHODS We analyzed 1,055 patients diagnosed with stage I-III breast cancer between 1990 and 1996. Variables studied incl...

Breast cancer prognostication and prediction: are we making progress?

Currently, much effort is being invested in the identification of new, accurate prognostic and predictive factors in breast cancer. Prognostic factors assess the patient's risk of relapse based on indicators such as intrinsic tumor biology and disease stage at diagnosis, and are traditionally used to identify patients who can be spared unnecessary adjuvant therapy based only on the risk of rela...

Homeobox B13 in breast cancer – Prediction of tamoxifen benefit

A major issue in the management of breast cancer is to identify patients who are less likely to be cured after primary treatment and would benefit from adjuvant chemotherapy. Of great importance is also identification of patients with only local disease who traditionally would be given chemotherapy but would survive without. In this thesis we have validated the utility of the two-gene ratio HOX...

Breast Cancer Prognostication and Risk Prediction in the Post-Genomic Era